

**PE/Cy5 anti-human CD19**

**Catalog # / Size:** 2111045 / 25 tests  
2111050 / 100 tests

**Clone:** HIB19

**Isotype:** Mouse IgG1,  $\kappa$


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** V CD19.11

**Concentration:** Lot-specific



Human peripheral blood lymphocytes stained with HIB19 PE/Cy5

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>8</sup> and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/ $\mu$ g, Azide-Free, 0.2  $\mu$ m filtered) is recommended for functional assays (Cat. No. 302214).

**Application References:**

- Schlossman S, *et al.* 1995. Leucocyte Typing V. Oxford University Press. New York.
- Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.
- Joseph A, *et al.* 2010. *J. Virol.* 84:6645. [PubMed](#)
- Wang X, *et al.* 2010. *Haematologica.* 95:884. (FC) [PubMed](#)
- Walker JD, *et al.* 2009. *J. Immunol.* 182:1548. (Block) [PubMed](#)
- Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
- Hansen A, *et al.* 2002. *Arthritis Rheum.* 46:2160. (IHC)
- Wang LX, *et al.* 2014. *PNAS.* 111:3146. [PubMed](#)
- Boisson B, *et al.* 2015. *J Exp Med.* 212:939. [PubMed](#)

**Description:** CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

- Antigen** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.
- References:** 2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.